A new vaccination method for exogenous and endogenous antigen initiated disorders

Vaccinations: Procedures, Types and Controversy

Volumn , Issue , 2012, Pages 75-98

  Barabas, Arpad Zsigmond ^a   Cole, Chad Douglas ^b   Lafreniere, Rene ^a   Weir, Donald Mackay ^c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Autoimmunity; Membranous glomerulonephritis; Modified vaccination technique

Indexed keywords

EID: 84891971726     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (79)

1. Agmon-Levin, N., Paz, Z., Israeli, E., Shoenfeld, Y. Vaccines and autoimmunity. Nat. Rev. Rheumatol., 2009, 5, 648-52.
2. Alballa, S., Fritzler, M., Davis, P. A case of drug induced lupus due to carbamazepine. J. Rheumatol., 1987, 14, 599-600.
3. Andreakos, E., Taylor, P. C., Feldmann, M. Monoclonal antibodies in immune and inflammatory diseases. Curr. Opin. Biotechnol., 2002, 13, 615-20.
4. Arbuckle, M. R., McClain, M. T., Rubertone, M. V., Scofield, R. H., Dennis, G. J., James, J.A. et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl. J. Med., 2003, 349, 1526-33.
5. Avrameas, S. Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'. Immunol. Today, 1991, 12, 154-9.
6. Barabas, A. Z., Cole, C. D., Barabas, A. D., Bahlis, N. J., Lafreniere, R. New vaccination technology for endogenous antigen-derived ailments. IDrugs, 2008, 11, 111-5.
7. Barabas, A. Z., Cole, C. D., Barabas, A. D., Bahlis, N. J., Lafreniere, R. A vaccination technique to combat presently untreatable chronic ailments. BioProcessing Journal, 2007, 6, 12-8.
8. Barabas, A. Z., Cole, C. D., Barabas, A. D., Barabas, A. N., Lafreniere, R. Reduced incidence of slowly progressive Heymann nephritis in rats immunized with a modified vaccination technique. Clin. Dev. Immunol., 2006, 13, 17-24.
9. Barabas, A. Z., Cole, C. D., Barabas, A. D., Cowan, J. M., Yoon, C. S., Waisman, D.M. et al. Presence of immunoglobulin M antibodies around the glomerular capillaries and in the mesangium of normal and passive Heymann nephritis rats. Int. J. Exp. Pathol., 2004, 85, 201-12.
10. Barabas, A. Z., Cole, C. D., Barabas, A. D., Graeff, R. M., Lafreniere, R., Weir, D.M. Correcting autoimmune anomalies in autoimmune disorders by immunological means, employing the modified vaccination technique. Autoimmun. Rev., 2009, 8, 552-7.
11. Barabas, A. Z., Cole, C. D., Barabas, A. D., Graeff, R. M., Lafreniere, R., Weir, D.M. Modified vaccination technique for prophylactic and therapeutic applications to combat endogenous antigen-induced disorders. Scandinavian Journal of Immunology, 2010, 71, 125-33.
12. Barabas, A. Z., Cole, C. D., Barabas, A. D., Lafreniere, R. Production of a new model of slowly progressive Heymann nephritis. Int. J. Exp. Pathol., 2003, 84, 245-58.
13. Barabas, A. Z., Cole, C. D., Barabas, A. D., Lafreniere, R. Down-regulation of pathogenic autoantibody response in a slowly progressive Heymann nephritis kidney disease model. Int. J. Exp. Pathol., 2004, 85, 321-34.
14. Barabas, A. Z., Cole, C. D., Barabas, A. D., Lafreniere, R. Production of Heymann nephritis by a chemically modified renal antigen. Int. J. Exp. Pathol., 2004, 85, 277-85.
15. Barabas, A. Z., Cole, C. D., Barabas, A. D., Lafreniere, R. Downregulation of a pathogenic autoantibody response by IgM autoantibodies directed against the nephritogenic antigen in slowly progressive Heymann nephritis. Pathol. Int., 2006, 56, 181-90.
16. Barabas, A. Z., Cole, C. D., Barabas, A. D., Lafreniere, R. A modified vaccination technique for the prevention and treatment of an experimental autoimmune kidney disease. Ann. N Y Acad. Sci., 2007, 1110, 619-29.
17. Barabas, A. Z., Cole, C. D., Barabas, A. D., Lafreniere, R. Preventative and therapeutic vaccination to combat an experimental autoimmune kidney disease. Biologics: Targets and Therapy, 2007, 1, 59-68.
18. Barabas, A. Z., Cole, C. D., Kovacs, Z. B., Lafreniere, R. Elevated antibody response by antigen presentation in immune complexes. Med. Sci. Monit., 2007, 13, BR119-BR124.
19. Barabas, A. Z., Cole, C. D., Lafreniere, R., Weir, D. M. Prophylactic and therapeutic application of a new vaccination technique for combating autoimmune disorders. In Conrad K, Chan EKL, Fritzler MJ, Humbel RL, Meroni PL, Shoenfeld Y, editors. From prediction to prevention of autoimmune diseases - Report on the 10th Dresden symposium on autoantibodies held in Dresden on September 22-25, 2011. Berlin: PABST Science Publishers, 2011, 519-39.
20. Barabas, A. Z., Cole, C. D., Weir, D. M., Lafreniere, R. Immunopathological events in an experimental autoimmune kidney disease and how those events can be terminated to regain tolerance to self. In Petrov M, editor. Autoimmune disorders: symptoms, diagnosis and treatment. Hauppauge NY: Nova Science Publishers, Inc., 2011, 35-66.
21. Barabas, A. Z., Lafreniere, R. Antigen-specific down-regulation of immunopathological events in an experimental autoimmune kidney disease. Autoimmun. Rev., 2005, 4, 565-70.
22. Barabas, A. Z., Nagi, A. H., Lannigan, R., Womersley, R.A. The effect of cortisone treatment on autologous immune complex glomerulonephritis in rats. Br. J. Exp. Pathol., 1970, 51, 541-6.
23. Barabas, A. Z., Weir, D. M., Cole, C. D., Barabas, A. D., Bahlis, N. J., Graeff, R.M. et al. Preventing and treating chronic disorders using the modified vaccination technique. Front. Biosci., 2009, 14, 3892-8.
24. Blank, M., Shoenfeld, Y. B-cell targeted therapy in autoimmunity. J. Autoimmun., 2007, 28, 62-8.
25. Boes, M., Schmidt, T., Linkemann, K., Beaudette, B. C., Marshak-Rothstein, A., Chen, J. Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc. Natl. Acad. Sci. U S A, 2000, 97, 1184-9.
26. Brown, B. A., Torabi, M. Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre. Drug Safety, 2011, 34, 117-23.
27. Byrd, J. C., Waselenko, J. K., Keating, M., Rai, K., Grever, M.R. Novel therapies for chronic lymphocytic leukemia in the 21st century. Semin. Oncol, 2000, 27, 587-97.
28. Byrd, J. C., Waselenko, J. K., Maneatis, T. J., Murphy, T., Ward, F. T., Monahan, B.P. et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J. Clin. Oncol., 1999, 17, 791-5.
29. Challice, J., Barabas, A. Z., Cornish, J., Bruce, J. W., Lannigan, R. Passive Heymann nephritis in pre- and post-natal rats. Br. J. Exp. Pathol., 1986, 67, 915-24.
30. Cornish, J., Barabas, A. Z., Lannigan, R. Modified immunofluorescent antibody test: demonstration of nephritogenic antigen in glomeruli of rats. Diagn. Immunol., 1984, 2, 133-6.
31. Dorner, T., Radbruch, A., Burmester, G.R. B-cell-directed therapies for autoimmune disease. Nat. Rev. Rheumatol., 2009, 5, 433-41.
32. Ebringer, A. Molecular mimicry as the basis of a new theory of autoimmunity. In: Zouali, M., editor. Frontiers in Autoimmunity: fundamental aspects and clinical perspectives. Amsterdam Netherlands: IOS Press, 2003, 79-99.
33. Ebringer, A., Thorpe, C., Pirt, J., Wilson, C., Cunningham, P., Ettelaie, C. Bovine spongiform encephalopathy: is it an autoimmune disease due to bacteria showing molecular mimicry with brain antigens? Environ. Health Perspect., 1997, 105, 1172-4.
34. Ellis, J.,H., Barber, K. A., Tutt, A., Hale, C., Lewis, A. P., Glennie, M.J. et al. Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma. J. Immunol., 1995, 155, 925-37.
35. Feldmann, M., Steinman, L. Design of effective immunotherapy for human autoimmunity. Nature, 2005, 435, 612-9.
36. Glassock, R.J. The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey. Am. J. Kidney Dis., 2010, 56, 157-67.
37. Greenwald, P., Clifford, C. K., Milner, J.A. Diet and cancer prevention. Eur. J. Cancer, 2001, 37, 948-65.
38. Heymann, W., Hackel, D. B., Harwood, S., Wilson, S. G., Hunter, J.L. P. Production of nephritic syndrome in rats by Freund's adjuvant and rat kidney suspensions. Proc. Soc. Exp. Biol. Med., 1959, 100, 660-4.
39. Hjelm, F., Carlsson, F., Getahun, A., Heyman, B. Antibody-mediated regulation of the immune response. Scand. J. Immunol., 2006, 64, 177-84.
40. Hogan, S. L., Muller, K. E., Jennette, J. C., Falk, R.J. A review of therapeutic studies of idiopathic membranous glomerulopathy. Am. J. Kidney Dis., 1995, 25, 862-75.
41. Jiang, X., Khursigara, G., Rubin, R.L. Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils. Science, 1994, 266, 810-3.
42. Kabe, K. L., Kolesar, J.M. Role of trastuzumab in adjuvant therapy for locally invasive breast cancer. Am. J. Health Syst. Pharm., 2006, 63, 527-33.
43. Kerjaschki, D. Pathogenetic concepts of membranous glomerulopathy (MGN). J. Nephrol. 2000, 2000, 13, S96-100.
44. Kerjaschki, D., Farquhar, M.G. Immunocytochemical localization of the Heymann nephritis antigen (GP330) in glomerular epithelial cells of normal Lewis rats. J. Exp. Med., 1983, 157, 667-86.
45. Kerjaschki, D., Horvat, R., Binder, S., Susani, M., Dekan, G., Ojha, P.P. et al. Identification of a 400-kd protein in the brush borders of human kidney tubules that is similar to gp330, the nephritogenic antigen of rat Heymann nephritis. Am. J. Pathol., 1987, 129, 183-91.
46. Kerjaschki, D., Neale, T.J. Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis). J. Am. Soc. Nephrol., 1996, 7, 2518-26.
47. Leandro, M. J., Edwards, J. C., Cambridge, G., Ehrenstein, M. R., Isenberg, D.A. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum., 2002, 46, 2673-7.
48. Makker, S. P., Makker, D.M. A simple technique for detecting the antigen of Heymann nephritis in glomeruli by immunofluorescence. Clin. Exp. Immunol., 1986, 64, 615-22.
49. Manson, J. J., Mauri, C., Ehrenstein, M.R. Natural serum IgM maintains immunological homeostasis and prevents autoimmunity. Springer Semin. Immunopathol., 2005, 26, 425-32.
50. Manz, R. A., Arce, S., Cassese, G., Hauser, A. E., Hiepe, F., Radbruch, A. Humoral immunity and long-lived plasma cells. Curr. Opin. Immunol., 2002, 14, 517-21.
51. Marrack, P., Scott-Browne, J., MacLeod, M.K. Terminating the immune response. Immunol. Rev., 2010, 236, 5-10.
52. Matsukawa, W., Hara, S., Yoshida, F., Suzuki, N., Fukatsu, A., Yuzawa, Y. et al. Effects of a new immunosuppressive agent, FK506, in rats with active Heymann nephritis. J. Lab. Clin. Med., 1992, 119, 116-23.
53. Mavromatis, B. H., Cheson, B.D. Novel therapies for chronic lymphocytic leukemia. Blood Rev., 2004, 18, 137-48.
54. Mevorach, D., Mascarenhas, J. O., Gershov, D., Elkon, K.B. Complement-dependent clearance of apoptotic cells by human macrophages. J. Exp. Med., 1998, 188, 2313-20.
55. Mokhtarian, F., Zhang, Z., Shi, Y., Gonzales, E., Sobel, R.A. Molecular mimicry between a viral peptide and a myelin oligodendrocyte glycoprotein peptide induces autoimmune demyelinating disease in mice. J. Neuroimmunol., 1999, 95, 43-54.
56. Molina, V., Shoenfeld, Y. Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity, 2005, 38, 235-45.
57. Nangaku, M., Pippin, J., Richardson, C. A., Schulze, M., Young, B. A., Alpers, C.E. et al. Beneficial effects of systemic immunoglobulin in experimental membranous nephropathy. Kidney Int., 1996, 50, 2054-62.
58. Noble, B., Van Liew, J. B., Brentjens, J. R., Andres, G.A. Effect of reimmunization with Fx1A late in the course of Heymann nephritis. Lab. Invest., 1982, 47, 427-36.
59. Ogden, C. A., Kowalewski, R., Peng, Y., Montenegro, V., Elkon, K.B. IgM is required for efficient complement mediated phagocytosis of apoptotic cells in vivo. Autoimmunity, 2005, 38, 259-64.
60. Orbach, H., Shoenfeld, Y. Vaccination infection and autoimmunity: myth and reality VIAMR 2005-10-26-28, Beau-Rivage Palace Hotel, Lausanne, Switzerland. Autoimmun. Rev., 2007, 6, 261-6.
61. Perna, A., Schieppati, A., Zamora, J., Giuliano, G. A., Braun, N., Remuzzi, G. Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am. J. Kidney. Dis., 2004, 44, 385-401.
62. Pirofsky, B., Kinzey, D.M. Intravenous immune globulins. A review of their uses in selected immunodeficiency and autoimmune diseases. Drugs, 1992, 43, 6-14.
63. Quartier, P., Potter, P. K., Ehrenstein, M. R., Walport, M. J., Botto, M. Predominant role of IgM-dependent activation of the classical pathway in the clearance of dying cells by murine bone marrow-derived macrophages in vitro. Eur. J. Immunol., 2005, 35, 252-60.
64. Schulze, C., Munoz, L. E., Franz, S., Sarter, K., Chaurio, R. A., Gaipl, U.S. et al. Clearance deficiency--a potential link between infections and autoimmunity. Autoimmun. Rev., 2008, 8, 5-8.
65. Segal, D. M., Weiner, G. J., Weiner, L.M. Bispecific antibodies in cancer therapy. Curr. Opin. Immunol., 1999, 11, 558-62.
66. Singh, A. K., Makker, S.P. Circulatory antigens of Heymann nephritis. I. Identification and partial characterization. Immunology, 1986, 57, 467-72.
67. Singh, A. K., Schwartz, M.M. Circulatory antigen of Heymann nephritis. II. Isolation of a 70,000 MW antigen from normal rat serum which cross-reacts with Heymann nephritis antigen. Immunology, 1986, 59, 451-8.
68. Totoritis, M. C., Rubin, R.L. Drug-induced lupus. Genetic, clinical, and laboratory features. Postgrad. Med., 1985, 78, 149-61.
69. Townsend, M. J., Monroe, J. G., Chan, A.C. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol. Rev., 2010, 237, 264-83.
70. Tsukada, Y., Ono, K., Maezawa, A., Yano, S., Naruse, T. A major pathogenic antigen of Heymann nephritis is present exclusively in the renal proximal tubule brush border--studies with a monoclonal antibody against pronase-digested tubular antigen. Clin. Exp. Immunol., 1994, 96, 303-10.
71. Turner-Stokes, T., Lu, T. Y., Ehrenstein, M. R., Giles, I., Rahman, A., Isenberg, D.A. The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. Rheumatology (Oxford), 2011, 50, 1401-8.
72. Weir, D.M. The immune response after tissue injury. Pathol. Eur., 1966, 1, 108-18.
73. Weir, D.M. The immunologicial consequences of cell death. Lancet, 1967, 2, 1071-3.
74. Weir, D.M. Altered antigens and autoimmunity. Vox. Sang., 1969, 16, 304-13.
75. Weir, D. M., Pinckard, R. N., Elson, C. J., Suckling, D.E. Naturally occurring anti-tissue antibodies in rat sera. Clin. Exp. Immunol., 1966, 1, 433-42.
76. Wermeling, F., Karlsson, M. C., McGaha, T.L. An anatomical view on macrophages in tolerance. Autoimmun. Rev., 2009, 9, 49-52.
77. Wucherpfennig, K.W. Mechanisms for the induction of autoimmunity by infectious agents. J. Clin. Invest., 2001, 108, 1097-104.
78. Yoshida, T., Mei, H., Dorner, T., Hiepe, F., Radbruch, A., Fillatreau, S. et al. Memory B and memory plasma cells. Immunol. Rev., 2010, 237, 117-39.
79. Yung, R. L., Johnson, K. J., Richardson, B.C. New concepts in the pathogenesis of drug-induced lupus. Lab. Invest., 1995, 73, 746-59.